Harrow, Inc. (HROW)

Market Cap	1.03B
Revenue (ttm)	169.14M
Net Income (ttm)	-33.41M
Shares Out	35.61M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	75.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,320
Open	29.63
Previous Close	30.00
Day's Range	28.80 - 30.00
52-Week Range	9.86 - 59.23
Beta	0.69
Analysts	Strong Buy
Price Target	55.40 (+91.5%)
Earnings Date	May 12, 2025

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic e...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW
• Website: https://www.harrow.com

Financial Performance

In 2023, Harrow's revenue was $130.19 million, an increase of 46.95% compared to the previous year's $88.60 million. Losses were -$24.41 million, 73.3% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $55.4, which is an increase of 91.50% from the latest price.

Price Target

$55.4

(91.50% upside)

Analyst Consensus: Strong Buy